ENOV
Enovis Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth +18.2% ·
share flow -9.1% ·
net new positions +15.4%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 148.61K | $2.70M | n/a | n/a |
| Q2 2026 | 91 | +1 | 44.48M | $916.26M | +11 | −11 |
| Q1 2026 | 94 | 0 | 43.44M | $983.72M | +7 | −7 |
| Q4 2025 | 94 | 0 | 46.98M | $1.22B | +1 | −1 |
| Q3 2025 | 15 | 0 | 23.49M | $712.80M | +1 | −1 |
| Q2 2025 | 12 | -1 | 21.15M | $663.36M | +1 | −2 |
| Q1 2025 | 10 | -3 | 4.37M | $166.84M | +1 | −4 |
| Q4 2024 | 13 | +2 | 4.81M | $211.07M | +3 | −1 |
| Q3 2024 | 10 | 0 | 3.56M | $153.33M | +1 | −1 |
| Q2 2024 | 10 | n/a | 3.60M | $162.77M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.73M | n/a | $76.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Citadel Advisors ✦ | 994.28K | +263.2% | $43.63M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 923.67K | +0.2% | $40.54M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 572.58K | -69.5% | $25.12M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 5 | Adage Capital Partners ✦ | 250.00K | New | $10.97M | 0.0% | New | 1 | SEC ↗ |
| 6 | Marshall Wace ✦ | 141.53K | New | $6.21M | 0.0% | New | 1 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 63.55K | New | $2.79M | 0.0% | New | 1 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 56.60K | +180.8% | $2.48M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 9 | T. Rowe Price ✦ | 38.75K | -84.7% | $1.70M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | PRIMECAP Management ✦ | 11.97K | -86.0% | $525,112 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 9.85K | -89.9% | $432,174 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | GAMCO Investors ✦ | 8.83K | +10.1% | $387,373 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Bridgewater Associates ✦ | 5.92K | -66.4% | $259,550 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $10.97M | 0.0% |
| Marshall Wace | $6.21M | 0.0% |
| Point72 Asset Management | $2.79M | 0.0% |
Exited
| Two Sigma Investments | $204,186 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4 holders, 12.22M shares, $11.78M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · Chief Administrative… · 2.66K sh @ 18.80 · $50,008
Officer, Director · Chief Executive… · 13.04K sh @ 19.15 · $249,620
Officer · Chief Administrative… · 5.14K sh @ 19.46 · $100,024
Officer · Chief Administrative… · 2.46K sh @ 20.32 · $49,947
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology